Please use this identifier to cite or link to this item: http://hdl.handle.net/10419/68018
Authors: 
Ruane, Frances P.
Zhang, Xiaheng
Year of Publication: 
2007
Series/Report no.: 
Working Paper, The Economic and Social Research Institute (ESRI), Dublin 211
Abstract: 
Differences in regulations, technical standards and national medical cultures across EU member states created a highly segmented pharmaceutical market in Europe prior to the implementation of the Single Market Programme. The subsequent reduction in non-tariff barriers to trade would be expected to have an impact on where pharmaceutical multinationals locate production within the EU. Using discrete-choice models, we study the determinants of multinationals' location choices in terms of expanded production at existing facilities. Our results support the findings of New Economic Geography models that predict reduced rather than increased agglomeration in the face of trade-cost reductions.
Subjects: 
economic geographic
location choice
discrete choice models
European integration
FDI
JEL: 
F15
F23
R12
Document Type: 
Working Paper

Files in This Item:
File
Size





Items in EconStor are protected by copyright, with all rights reserved, unless otherwise indicated.